Wenjun Wu

机构：Shanghai University, Nanjing University of Posts and Telecommunications, Xi'an Botanical Garden of Shaanxi Province, Ningxia Medical University, Ningxia Medical University General Hospital, Chung Shan Medical University · ORCID：0009-0009-8369-9059

发表论文 44 篇 · 总被引 477 次 · h-index 13

代表论文

• Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication (2021 · Blood Cancer Journal · 被引 52)
• XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB (2018 · Molecular Cancer Therapeutics · 被引 47)
• A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria (2023 · The Lancet Regional Health - Western Pacific · 被引 38)
• Arbutin Alleviates the Liver Injury of α-Naphthylisothiocyanate-induced Cholestasis Through Farnesoid X Receptor Activation (2021 · Frontiers in Cell and Developmental Biology · 被引 19)
• Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2 (2021 · Blood Advances · 被引 17)
• Association of endothelial nitric oxide synthase ( eNOS ) polymorphisms with EGFR -mutated lung adenocarcinoma in Taiwan (2018 · Journal of Cancer · 被引 16)